Skip to Main Content

Geert Kersten, the CEO of drugmaker Cel-Sci, stopped communicating publicly soon after the company’s cancer drug failed to prolong the survival of patients in a large clinical trial last June. Privately, Kersten is talking to select investors. And what he’s telling them could land him and Cel-Sci in trouble with federal regulators.

During a conference call last Wednesday, Kersten tipped off an invitation-only group of investors and brokers about Cel-Sci’s plan to issue a “major press release” later this week, possibly on Thursday, related to its cancer drug, called Multikine. The press release was to be issued simultaneously with a posting of Multikine clinical trial data on the government’s website, Kersten said.


A participant provided STAT with access to the call and I heard Kersten’s entire presentation live. He also answered questions from listeners. The call was organized by an investor relations firm and lasted about 30 minutes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.